Select one of the papers from the list below and read it.
1. Describe the paper, its context, and comment on the value of the research, focusing on trial design, statistical techniques used to minimize bias, statistical methodology and approaches used to ensure correctness of inferences. The study findings including the key results should be discussed. (25%).
2. Give a critique of the methodological steps used by the researchers for the study. Take into account the review questions from the Critical Assessment Skills Programme (CASP) http://www.casp-uk.net/casp-tools-checklists, plus other issues of relevance. Discuss specifically any methodological limitations, and how these limitations impact on the conclusions of the study (40%).
Indicate, where relevant, how these limitations could have been better managed (10%).
3. What original clinical study would you conduct to further investigate the author’s findings, or some of the findings identified? Describe the study objectives, trial design, sample size, statistical methodology, the data collection and data management of your study (25%).
Word count guidance: 1500 words (references, tables, headings not included)
i dont have a minimum number of refernces but you will probaly have to include some, especially in part 3.
If you go over 1500 words by using tables/ references, i will tip at the end for the extra work.
Suggested papers:
Becker MA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61. https://www.nejm.org/doi/full/10.1056/NEJMoa050373
Beigel JH et al. Remdesivir for the treatment of Covid-19 — Final Report. N Engl J Med 2020; 383: 1813-26. https://www.nejm.org/doi/full/10.1056/nejmoa2007764
Caplin ME et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-33. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1316158#:~:text=Lanreotide%20was%20associated%20with%20significantly,Ki%2D67%20%3C10%25).
Wang Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569-78. https://www.sciencedirect.com/science/article/pii/S0140673620310229